| Bioactivity | GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor with IC50s of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO), respectively[1]. | ||||||||||||
| Target | IC50: 2.3 nM (human KMO), 0.7 nM (Pf-KMO) | ||||||||||||
| Name | GSK 366 | ||||||||||||
| CAS | 1953157-39-5 | ||||||||||||
| Formula | C17H16ClN3O4 | ||||||||||||
| Molar Mass | 361.78 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hutchinson JP, et al. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827. |
GSK 366
CAS: 1953157-39-5 F: C17H16ClN3O4 W: 361.78
GSK 366 is a potent kynurenine-3-monooxygenase (KMO) inhibitor with IC50s of 2.3 nM and 0.7 nM for human KMO and P. fluo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.